<p>CureVac（納斯達克代碼：CVAC - 獲取免費報告）的股票在週五交易前出現了跳空上漲。該股票之前收於 3.26 美元，但開盤價為 3.37 美元。CureVac 的股票最後交易價格為 3.35 美元，成交量為 42,511 股。</p>
<h2>華爾街分析師預測增長</h2>
<ul>
<li>2 只小盤股將在牛市中大放異彩</li>
</ul>
<p>另外，JMP 證券在 2 月 14 日的研究報告中重申了對 CureVac 的 “市場表現優於大盤” 評級，並設定了 16.00 美元的目標價。</p>
<p><strong>查看我們關於 CVAC 的最新報告</strong></p>
<h2>CureVac 股票表現</h2>
<ul>
<li>3 只因 COVID 復甦而值得購買的股票</li>
</ul>
<p>該公司的市值為 7.6051 億美元，市盈率為 6.15，貝塔係數為 2.48。該股票的 50 日移動平均價格為 3.04 美元，200 日移動平均價格為 3.17 美元。公司的債務股本比率為 0.05，速動比率為 6.19，流動比率為 6.20。</p>
<p>CureVac（納斯達克代碼：CVAC - 獲取免費報告）最近於 4 月 10 日發佈了季度財報。該公司報告每股收益（EPS）為-0.15 美元，低於市場共識預期的-0.14 美元，差距為 0.01 美元。CureVac 的淨利潤率為 20.72%，股本回報率為 21.98%。該公司在本季度的收入為 1544 萬美元，而市場共識預期為 640 萬美元。整體來看，研究分析師預計 CureVac 在當前財政年度將發佈 0.72 美元的每股收益。</p>
<h2>對 CureVac 的對沖基金看法</h2>
<p>對沖基金和其他機構投資者最近增加或減少了對該股票的持倉。Jane Street Group LLC 在第三季度將其在 CureVac 的持股比例提高了 239.0%。Jane Street Group LLC 目前擁有 79,247 股該公司的股票，價值 235,000 美元，此前在上個季度又購買了 55,867 股。巴克萊 PLC 在第三季度收購了 CureVac 的新股份，價值約 67,000 美元。中國泛海資產管理有限公司在第四季度將其在 CureVac 的持股提高了 10.3%。中國泛海資產管理有限公司目前擁有 47,568 股該公司的股票，價值 162,000 美元，此前在此期間又收購了 4,425 股。Signaturefd LLC 在第四季度將其在 CureVac 的持股增加了 29.2%。Signaturefd LLC 目前擁有 36,140 股該公司的股票，價值 123,000 美元，此前在上個季度又購買了 8,170 股。最後，Geode Capital Management LLC 在第四季度將其在 CureVac 的持股增加了 10.3%。Geode Capital Management LLC 目前擁有 241,750 股該公司的股票，價值 824,000 美元，此前在此期間又購買了 22,491 股。17.26% 的股票由機構投資者持有。</p>
<h2>CureVac 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>CureVac N.V.是一家生物製藥公司，專注於開發基於信使核糖核酸（mRNA）的各種變革性藥物。它正在開發預防性疫苗，例如針對 SARS-CoV-2 的 mRNA 疫苗候選者 CV2CoV，目前處於第一階段臨牀試驗；CV7202 用於狂犬病治療，亦處於第一階段臨牀試驗；以及用於治療多價季節性流感的 CVSQIV；Flu SV mRNA 用於治療核苷酸、單抗季節性流感。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票比 CureVac 更具吸引力</li>
<li>投資者需要了解即將上市的 IPO</li>
<li>空頭最近放棄了這三隻股票</li>
<li>內部交易可能不會告訴你你想知道的</li>
<li>今年表現優於市場的三隻無聊股票</li>
<li>什麼是股息競爭者？投資股息競爭者</li>
<li>如果你想購買 AbbVie 但沒有，現在仍然有機會購買</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 CureVac 嗎？</h2>
<p>在考慮 CureVac 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 CureVac 並不在名單上。</p>
<p>雖然 CureVac 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

CVAC

<p>CureVac（納斯達克代碼：CVAC）股價在開盤前從 3.26 美元跳漲至 3.37 美元，最終收於 3.35 美元，成交量為 42,511 股。JMP Securities 維持 “市場表現優於大盤” 的評級，目標價為 16.00 美元。該公司報告的季度每股收益為（-0.15 美元），未達到預期，但收入為 1544 萬美元，超出預期。CureVac 專注於基於 mRNA 的藥物，市值為 7.6051 億美元。機構投資者持有該股票的 17.26%，多家對沖基金的持股比例顯著增加</p>

<p>Shares of CureVac (NASDAQ:CVAC - Get Free Report) gapped up prior to trading on Friday . The stock had previously closed at $3.26, but opened at $3.37. CureVac shares last traded at $3.35, with a volume of 42,511 shares trading hands.</p>
<div class="lb-trans"><p>CureVac（納斯達克代碼：CVAC - 獲取免費報告）的股票在週五交易前出現了跳空上漲。該股票之前收於 3.26 美元，但開盤價為 3.37 美元。CureVac 的股票最後交易價格為 3.35 美元，成交量為 42,511 股。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><ul>
<li>2 Small-Cap Stocks Set to Shine in a Bull Market</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只小盤股將在牛市中大放異彩</li>
</ul>
</div><p>Separately, JMP Securities reiterated a &#34;market outperform&#34; rating and set a $16.00 price objective on shares of CureVac in a research note on Friday, February 14th.</p>
<div class="lb-trans"><p>另外，JMP 證券在 2 月 14 日的研究報告中重申了對 CureVac 的 “市場表現優於大盤” 評級，並設定了 16.00 美元的目標價。</p>
</div><p><strong>View Our Latest Report on CVAC</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 CVAC 的最新報告</strong></p>
</div><h2>CureVac Stock Performance</h2>
<div class="lb-trans"><h2>CureVac 股票表現</h2>
</div><ul>
<li>3 Stocks to Buy For the COVID Resurgence</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只因 COVID 復甦而值得購買的股票</li>
</ul>
</div><p>The company has a market capitalization of $760.51 million, a P/E ratio of 6.15 and a beta of 2.48. The stock's fifty day moving average price is $3.04 and its 200-day moving average price is $3.17. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.19 and a current ratio of 6.20.</p>
<div class="lb-trans"><p>該公司的市值為 7.6051 億美元，市盈率為 6.15，貝塔係數為 2.48。該股票的 50 日移動平均價格為 3.04 美元，200 日移動平均價格為 3.17 美元。公司的債務股本比率為 0.05，速動比率為 6.19，流動比率為 6.20。</p>
</div><p>CureVac (NASDAQ:CVAC - Get Free Report) last released its quarterly earnings data on Thursday, April 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.01). CureVac had a net margin of 20.72% and a return on equity of 21.98%. The business had revenue of $15.44 million during the quarter, compared to the consensus estimate of $6.40 million. As a group, research analysts anticipate that CureVac will post 0.72 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>CureVac（納斯達克代碼：CVAC - 獲取免費報告）最近於 4 月 10 日發佈了季度財報。該公司報告每股收益（EPS）為-0.15 美元，低於市場共識預期的-0.14 美元，差距為 0.01 美元。CureVac 的淨利潤率為 20.72%，股本回報率為 21.98%。該公司在本季度的收入為 1544 萬美元，而市場共識預期為 640 萬美元。整體來看，研究分析師預計 CureVac 在當前財政年度將發佈 0.72 美元的每股收益。</p>
</div><h2>Hedge Funds Weigh In On CureVac</h2>
<div class="lb-trans"><h2>對 CureVac 的對沖基金看法</h2>
</div><p>Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC lifted its stake in shares of CureVac by 239.0% during the 3rd quarter. Jane Street Group LLC now owns 79,247 shares of the company's stock worth $235,000 after buying an additional 55,867 shares during the last quarter. Barclays PLC acquired a new stake in CureVac during the third quarter worth approximately $67,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of CureVac by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 47,568 shares of the company's stock worth $162,000 after acquiring an additional 4,425 shares during the period. Signaturefd LLC grew its position in shares of CureVac by 29.2% in the fourth quarter. Signaturefd LLC now owns 36,140 shares of the company's stock valued at $123,000 after purchasing an additional 8,170 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of CureVac by 10.3% during the fourth quarter. Geode Capital Management LLC now owns 241,750 shares of the company's stock worth $824,000 after purchasing an additional 22,491 shares during the period. 17.26% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>對沖基金和其他機構投資者最近增加或減少了對該股票的持倉。Jane Street Group LLC 在第三季度將其在 CureVac 的持股比例提高了 239.0%。Jane Street Group LLC 目前擁有 79,247 股該公司的股票，價值 235,000 美元，此前在上個季度又購買了 55,867 股。巴克萊 PLC 在第三季度收購了 CureVac 的新股份，價值約 67,000 美元。中國泛海資產管理有限公司在第四季度將其在 CureVac 的持股提高了 10.3%。中國泛海資產管理有限公司目前擁有 47,568 股該公司的股票，價值 162,000 美元，此前在此期間又收購了 4,425 股。Signaturefd LLC 在第四季度將其在 CureVac 的持股增加了 29.2%。Signaturefd LLC 目前擁有 36,140 股該公司的股票，價值 123,000 美元，此前在上個季度又購買了 8,170 股。最後，Geode Capital Management LLC 在第四季度將其在 CureVac 的持股增加了 10.3%。Geode Capital Management LLC 目前擁有 241,750 股該公司的股票，價值 824,000 美元，此前在此期間又購買了 22,491 股。17.26% 的股票由機構投資者持有。</p>
</div><h2>CureVac Company Profile</h2>
<div class="lb-trans"><h2>CureVac 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.</p>
<div class="lb-trans"><p>CureVac N.V.是一家生物製藥公司，專注於開發基於信使核糖核酸（mRNA）的各種變革性藥物。它正在開發預防性疫苗，例如針對 SARS-CoV-2 的 mRNA 疫苗候選者 CV2CoV，目前處於第一階段臨牀試驗；CV7202 用於狂犬病治療，亦處於第一階段臨牀試驗；以及用於治療多價季節性流感的 CVSQIV；Flu SV mRNA 用於治療核苷酸、單抗季節性流感。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than CureVac</li>
<li>What Investors Need to Know About Upcoming IPOs</li>
<li>Short Sellers Gave Up on These 3 Names Recently</li>
<li>Insider Trades May Not Tell You What You Think</li>
<li>3 Boring Stocks Outperforming the Market This Year</li>
<li>What Are Dividend Contenders? Investing in Dividend Contenders</li>
<li>If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 CureVac 更具吸引力</li>
<li>投資者需要了解即將上市的 IPO</li>
<li>空頭最近放棄了這三隻股票</li>
<li>內部交易可能不會告訴你你想知道的</li>
<li>今年表現優於市場的三隻無聊股票</li>
<li>什麼是股息競爭者？投資股息競爭者</li>
<li>如果你想購買 AbbVie 但沒有，現在仍然有機會購買</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in CureVac Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 CureVac 嗎？</h2>
</div><p>Before you consider CureVac, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 CureVac 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CureVac wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 CureVac 並不在名單上。</p>
</div><p>While CureVac currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 CureVac 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

CureVac（納斯達克股票代碼：CVAC）股價跳空上漲的原因